India markets closed

    +374.87 (+0.79%)
  • Nifty 50

    +109.75 (+0.77%)
  • Dow

    +316.01 (+0.93%)
  • Nasdaq

    +163.95 (+1.19%)

    -3,657.75 (-0.09%)
  • CMC Crypto 200

    +22.22 (+1.76%)
  • Hang Seng

    +133.42 (+0.47%)
  • Nikkei

    +679.62 (+2.38%)

    -0.4704 (-0.52%)

    -1.0873 (-1.03%)

    -0.1010 (-0.49%)

    +0.0080 (+0.56%)

    -0.2780 (-0.49%)

Gamma Secretase Pipeline Review, H2 2020 -

·5-min read

The "Gamma Secretase - Pipeline Review, H2 2020" drug pipelines has been added to's offering.

'Gamma Secretase - Pipeline Review, H2 2020' outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

'Gamma Secretase - Pipeline Review, H2 2020'; Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Gamma Secretase (EC 3.4.23.) - Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain.

The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein.


  • The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)

  • The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

Key Topics Covered:


  • Report Coverage


Therapeutics Development

  • Products under Development by Stage of Development

  • Products under Development by Therapy Area

  • Products under Development by Indication

  • Products under Development by Companies

  • Products under Development by Universities/Institutes

Therapeutics Assessment

  • Assessment by Mechanism of Action

  • Assessment by Route of Administration

  • Assessment by Molecule Type

Companies Involved in Therapeutics Development

  • Adipo Therapeutics LLC

  • AlzeCure Pharma AB

  • Astellas Pharma Inc

  • Audion Therapeutics BV

  • Ayala Pharmaceuticals Inc

  • Eli Lilly and Co

  • Everfront Biotech Inc

  • F. Hoffmann-La Roche Ltd

  • Lipopharma Therapeutics SL

  • Merck & Co Inc

  • NeuroGenetic Pharmaceuticals Inc

  • Pharchoice Therapeutics Inc

  • Pipeline Therapeutics Inc

  • SpringWorks Therapeutics Inc

Drug Profiles

  • ACD-679

  • ACD-680

  • AL-101

  • AL-102

  • crenigacestat

  • dibenzazepine

  • EF-005

  • Gene Therapy to Activate PSEN1 for Heart Failure

  • GSI-34

  • LP-226A1

  • LY-3056480

  • NGP-555

  • nirogacestat hydrobromide

  • Peptides to Inhibit PSEN1 for Alzheimer's Disease

  • PIPE-505

  • RO-7185876

  • Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease

  • Small Molecules to Inhibit Gamma Secretase for Hearing Loss

  • Small Molecules to Inhibit PSEN1 for Alzheimer's Disease

  • Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease

Dormant Products

Discontinued Products

Product Development Milestones

  • Featured News & Press Releases

  • Sep 18, 2020: Ayala Pharmaceuticals presents positive interim data from phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma with notch activating mutations at ESMO 2020

  • Sep 16, 2020: SpringWorks Therapeutics announces collaboration with Children's Oncology Group to conduct a phase 2 clinical trial of nirogacestat in pediatric patients with desmoid tumors and reports publication of nirogacestat case series in pediatric/young adult desmoid tumor patients

  • Sep 14, 2020: Ayala Pharmaceuticals to host virtual KOL event reviewing interim data presented at ESMO 2020 from ongoing phase 2 accuracy trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma

  • Jul 27, 2020: Ayala Pharmaceuticals to present updated data from ongoing phase 2 ACCURACY trial of AL101 for the treatment of R/M adenoid cystic carcinoma at the European Society for Medical Oncology (ESMO) virtual congress 2020

  • Jul 23, 2020: Pipeline Therapeutics initiates Phase 1/2a clinical trial of PIPE-505 in sensorineural hearing loss

  • Jul 22, 2020: SpringWorks Therapeutics announces full enrollment of phase 3 DeFi trial evaluating nirogacestat in adult patients with desmoid tumors

  • Jun 22, 2020: SpringWorks Therapeutics announces dosing of first patient in phase 1b combination study evaluating Nirogacestat and GlaxoSmithKline's Belantamab Mafodotin for the treatment of Relapsed or Refractory Multiple Myeloma

  • Mar 18, 2020: SpringWorks Therapeutics announces issuance of new U.S. composition of matter patent to polymorphic form of Nirogacestat, extending patent protection into 2039

  • Mar 03, 2020: Ayala Pharmaceuticals granted U.S. FDA Fast Track Designation for AL101 for the treatment of recurrent or metastatic adenoid cystic carcinoma

  • Dec 09, 2019: Researchers present preclinical data showing synergistic activity of Springworks Therapeutics gamma secretase inhibitor (Nirogacestat) with glaxosmithkline's BCMA antibody-drug conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH ) Annual Meeting

  • Sep 30, 2019: Ayala Pharmaceuticals presents encouraging preliminary safety and efficacy data in patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with progressing disease and notch activating mutations from ongoing phase 2 clinical trial at ESMO

  • Sep 26, 2019: SpringWorks receives orphan status for nirogacestat in Europe

  • Sep 19, 2019: Ayala Pharmaceuticals announces presentation at the European Society for Medical Oncology (ESMO)

  • Aug 30, 2019: SpringWorks receives breakthrough status for desmoid tumour drug

  • May 20, 2019: Ayala Pharmaceuticals to present at ASCO Annual Meeting on investigational drug AL101 in adenoid cystic carcinoma and triple negative breast cancer


For more information about this drug pipelines report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900